ons connect logo

ons connect

Enzalutamide May Be a Promising Option for Metastatic, Castration-Resistant Prostate Cancer

Nurses working

The PREVAIL trial studied 17,000 men with asymptomatic or mildly symptomatic, metastatic, castration-resistant prostate cancer who had received androgen-deprivation therapy but not chemotherapy. The men were randomized to receive daily enzalutaminde (an androgen-receptor antagonist) or placebo. 

At 12 months, radiographic progression-free survival was higher in the enzalutamide group (65% versus 14%, respectively). Enzalutamide reduced the risk of radiographic progression by 81% and delayed the need for chemotherapy by a median of 17 months. Median time to chemotherapy was 28 months in the enzalutamide group versus 10.8 months in the placebo arm. 

Share This Article
Print this page Print this page

Add new comment